AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00846911
First received: February 18, 2009
Last updated: July 5, 2012
Last verified: July 2012
  Purpose

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.

This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.


Condition Intervention
Bronchitis, Chronic
Drug: Moxifloxacin (Avelox, BAY12-8039)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Time until improvement of acute exacerbation [ Time Frame: End of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time until cure of acute exacerbation [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • Severity of AECB according to Antonisen criteria [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Impact of AECB on daily life activities [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Safety of Avelox under daily life treatment conditions [ Time Frame: Throughout treatment ] [ Designated as safety issue: Yes ]

Enrollment: 2672
Study Start Date: April 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Moxifloxacin (Avelox, BAY12-8039)
Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00846911

Locations
Albania
Many Locations, Albania
Bosnia and Herzegovina
Many Locations, Bosnia and Herzegovina
Kazakhstan
Many Locations, Kazakhstan
Macedonia, The Former Yugoslav Republic of
Many Locations, Macedonia, The Former Yugoslav Republic of
Moldova, Republic of
Many Locations, Moldova, Republic of
Russian Federation
Many Locations, Russian Federation
Slovakia
Many Locations, Slovakia
Ukraine
Many Locations, Ukraine
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided by Bayer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Global Medical Affairs Head, Bayer HealthCare AG
ClinicalTrials.gov Identifier: NCT00846911     History of Changes
Other Study ID Numbers: 14689, AX0701, 13598, 13855, 13856, 13857, 14008, 14007, 14009
Study First Received: February 18, 2009
Last Updated: July 5, 2012
Health Authority: Albania: Ministry of Health Department of Pharmacy
Bosnia: Federal Ministry of Health
Kazakhstan: Ethical Commission
Moldova: Ministry of Health
Macedonia: Ministry of Health
Russia: Ethics Committee
Slovakia: State Institute for Drug Control
Ukraine: Central Ethical Comission

Keywords provided by Bayer:
Acute Exacerbation of Chronic Bronchitis (AECB) patients

Additional relevant MeSH terms:
Bronchitis
Bronchitis, Chronic
Pulmonary Disease, Chronic Obstructive
Acute Disease
Bronchial Diseases
Disease Attributes
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases
Respiratory Tract Infections
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on October 22, 2014